360 related articles for article (PubMed ID: 12701831)
1. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
2. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
4. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
5. The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa.
Mahomed H; Kibel M; Hawkridge T; Schaaf HS; Hanekom WA; Iloni K; Michaels D; Workman L; Verver S; Geiter L; Hussey GD
Pediatr Infect Dis J; 2006 Dec; 25(12):1167-72. PubMed ID: 17133164
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
7. Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries.
Brantsaeter AB; Romanus V; Andersen PH; Heldal E
Int J Tuberc Lung Dis; 2009 Apr; 13(4):440-5. PubMed ID: 19335948
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.
Marra F; Marra CA; Sadatsafavi M; Morán-Mendoza O; Cook V; Elwood RK; Morshed M; Brunham RC; Fitzgerald JM
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1414-24. PubMed ID: 19017451
[TBL] [Abstract][Full Text] [Related]
9. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
Hesseling AC; Marais BJ; Gie RP; Schaaf HS; Fine PE; Godfrey-Faussett P; Beyers N
Vaccine; 2007 Jan; 25(1):14-8. PubMed ID: 16959383
[TBL] [Abstract][Full Text] [Related]
10. Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016.
Kontturi A; Soini H; Ollgren J; Salo E
Clin Infect Dis; 2018 Sep; 67(8):1256-1261. PubMed ID: 29584893
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.
Oxlade O; Schwartzman K; Menzies D
Int J Tuberc Lung Dis; 2007 Jan; 11(1):16-26. PubMed ID: 17217125
[TBL] [Abstract][Full Text] [Related]
12. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?
Farhat M; Greenaway C; Pai M; Menzies D
Int J Tuberc Lung Dis; 2006 Nov; 10(11):1192-204. PubMed ID: 17131776
[TBL] [Abstract][Full Text] [Related]
13. BCG in Finland: changing from a universal to a selected programme.
Salo EP
Euro Surveill; 2006; 11(3):18-20. PubMed ID: 16567879
[TBL] [Abstract][Full Text] [Related]
14. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
15. To BCG or not to BCG? Preventing travel-associated tuberculosis in children.
Ritz N; Connell TG; Curtis N
Vaccine; 2008 Nov; 26(47):5905-10. PubMed ID: 18804139
[TBL] [Abstract][Full Text] [Related]
16. [Where do we stand with BCG vaccination programme in Japan?].
Mori T
Kekkaku; 2001 Apr; 76(4):385-97. PubMed ID: 11398330
[TBL] [Abstract][Full Text] [Related]
17. [Contemporary status of BCG vaccine in the world and in Serbia].
Pesut D
Med Pregl; 2004; 57 Suppl 1():37-40. PubMed ID: 15686220
[TBL] [Abstract][Full Text] [Related]
18. Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination.
Trnka L; Danková D; Svandová E
Tuber Lung Dis; 1993 Aug; 74(4):288-92. PubMed ID: 8219182
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings.
Manissero D; Lopalco PL; Levy-Bruhl D; Ciofi Degli Atti ML; Giesecke J
Vaccine; 2008 Apr; 26(18):2253-9. PubMed ID: 18400344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
